Impact of novel therapies on the efficacy of posttransplantation brentuximab vedotin maintenance in Hodgkin lymphoma

By afschroeder • May 30, 2026

Falade AS, Redd R, Desai SH, Moskowitz AJ, Shah H, Geyer SM, Ganesan N, Chang T, Othman T, Shah GL, Nedved A, Durani U, Ng LS, Baron K, Ong SY, Yoon K, Ansell SM, Iyengar S, Micallef I, Stuver R, Herrera AF, Mei M, Armand P, Merryman RW. Impact of novel therapies on the efficacy of posttransplantation brentuximab vedotin maintenance in Hodgkin lymphoma. Blood Adv. 2026 Jun 9;10(11):3833-3844. doi: 10.1182/bloodadvances.2025018683. PMID: 41894690.

Tags: Fellow, Hematology/Oncology, Olive View DoM, Publications

cfDNA derived gene signatures as surrogate for microvascular invasion in HCC

Gong R, Wang L, Xue D, Cai J, Jiang Y, Huang J, Zhu J, Li Z, Ke A, Shi G, Wang J, Wang W, Zheng[...]

Utilizing machine learning to identify multimodal signatures for patients who would benefit from the addition of tremelimumab to durvalumab and chemotherapy (TRIDENT)

Skoulidis F, Jabbour SK, Garon EB, Iyengar P, Scagliotti G, Ferrer L, Etchepare G, Gallinato O, Faure J, Bernard P, Colin T, Menu P, Lin[...]

Threading the Needle in Bladder Cancer: A Narrative Review of the Emerging Role of Integrative Oncology in Treatment-Related Adverse Events in the Era of Immunotherapy and Antibody-Drug Conjugates

Niknafs AM, Damron LF, Baclig NV, Iliopoulos M, Drakaki A. Threading the Needle in Bladder Cancer: A Narrative Review of the Emerging Role of Integrative[...]